trending Market Intelligence /marketintelligence/en/news-insights/trending/1hisipxm3gcfasvozir_zq2 content esgSubNav
In This List

Corindus' robotic-assisted surgery platform approved in Japan

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Corindus' robotic-assisted surgery platform approved in Japan

Corindus Vascular Robotics Inc. said Japan's Pharmaceutical and Medical Device Agency approved its robotic-assisted surgery platform.

The regulator approved the CorPath GRX system, a platform used in heart surgeries. Corindus said it is seeking reimbursement for CorPath GRX through the Japanese insurance system.

There is strong demand for robotic-assisted intervention in Japan, said President and CEO Mark Toland. About 250,000 percutaneous coronary interventions — a nonsurgical procedure for narrowing of the heart's arteries — are performed in Japan every year, making it one of the largest markets in the world for such procedures, the company said.

Japan Medicalnext Co. Ltd., a Mitsubishi Corp. unit, will distribute the platform in Japan.

The U.S. Food and Drug Administration previously approved Waltham, Mass.-based Corindus' CorPath GRX.